Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Research And Development Expense of $166.13 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -4.9% in Research And Development Expense from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $14.74 million | Q3 2010: $19.20 million | Q1 2011: $13.40 million | Q2 2011: $14.44 million | Q3 2011: $15.10 million | Q1 2012: $15.53 million | Q2 2012: $12.78 million | Q3 2012: $12.07 million | Q1 2013: $7.22 million | Q2 2013: $11.53 million | Q3 2013: $7.74 million | Q1 2014: $9.18 million | Q2 2014: $11.07 million | Q3 2014: $13.04 million | Q1 2015: $17.12 million | Q2 2015: $16.52 million | Q3 2015: $20.07 million | Q1 2016: $20.58 million | Q2 2016: $14.17 million | Q3 2016: $14.11 million | Q1 2017: $16.77 million | Q2 2017: $15.76 million | Q3 2017: $17.51 million | Q1 2018: $18.44 million | Q2 2018: $21.01 million | Q3 2018: $22.01 million | Q1 2019: $27.49 million | Q2 2019: $27.68 million | Q3 2019: $25.12 million | Q1 2020: $29.87 million | Q2 2020: $27.50 million | Q3 2020: $30.25 million | Q1 2021: $42.44 million | Q2 2021: $52.87 million | Q3 2021: $49.97 million | Q1 2022: $65.36 million | Q2 2022: $61.99 million | Q3 2022: $52.74 million | Q1 2023: $48.39 million | Q2 2023: $51.25 million | Q3 2023: $46.88 million | Q1 2024: $46.49 million | Q2 2024: $37.62 million | Q3 2024: $41.08 million | Q1 2025: $37.27 million | Q2 2025: $43.39 million | Q3 2025: $44.60 million.
- Over the full 17 years of available data (2009 to 2025), BIOCRYST PHARMACEUTICALS INC's Research And Development Expense has grown by 125.5%.
- Historical annual values: Fiscal year 2025: $166.13 million | Fiscal year 2024: $174.64 million | Fiscal year 2023: $216.57 million | Fiscal year 2022: $253.30 million | Fiscal year 2021: $208.81 million | Fiscal year 2020: $122.96 million | Fiscal year 2019: $107.07 million | Fiscal year 2018: $84.89 million | Fiscal year 2017: $66.96 million | Fiscal year 2016: $61.01 million | Fiscal year 2015: $72.76 million | Fiscal year 2014: $51.80 million | Fiscal year 2013: $41.94 million | Fiscal year 2012: $49.16 million | Fiscal year 2011: $57.25 million | Fiscal year 2010: $83.90 million | Fiscal year 2009: $73.66 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: